Gynecological cancer is one of the greatest challenges in treatment, as well as in prevention and early diagnosis, of the set of all diagnosed cancers. At the beginning of the twenty-first century, we have witnessed the arrival of new treatments, new surgical techniques, more precise tools for diagnosis and prognosis, and the great development of antitumoral products, which give patients new perspectives on their prognosis and evolution, including improvement in the patient’s quality of life. All of these are important factors in their recovery.
It is important that we know what resources are available: accurate diagnostic tools such as positron emission tomography–computed tomography (PET-CT), effective vaccination programs against the viruses that trigger various types of tumors, and also treatments based on surgery, chemotherapy, monoclonal antibodies, and other tools that enable us to offer patients confidence based on the safety and efficacy of the combination of these treatments.
Cancer prevention—through vaccination campaigns and, above all we can do, education as a key point—is the way to achieve a healthy population, as well as a better quality of life for patients.
KeywordsGynecological tumors Cancer treatment Sexual education HPV vaccines Cancer prevention Oncology nursing
- 2.Taking personalized medicine to heart. Nat Med. 2018;24:113.Google Scholar
- 3.Genetics Home Reference. What is the difference between precision medicine and personalized medicine? What about pharmacogenomics? https://ghr.nlm.nih.gov/primer/precisionmedicine/precisionvspersonalized. Accessed 26 Jan 2019.
- 6.National Comprehensive Cancer Network [NCCN]. NCCN clinical practice guidelines in oncology (NCCN guidelines®). Ovarian cancer including fallopian tube cancer and primary peritoneal cancer. Version 2.2018—March 9, 2018. https://www.nccn.org/professionals/physician_gls/pdf/ovarian.pdf. Accessed 26 Jan 2019.
- 8.Monk BJ, Herzog TJ, Kaye SB, Krasner CN, Vermorken JB, Muggia FM, Pujade-Lauraine E, Park YC, Parekh TV, Poveda AM. Trabectedin plus pegylated liposomal doxorubicin (PLD) versus PLD in recurrent ovarian cancer: overall survival analysis. Eur J Cancer. 2012;48(15):2361–8. https://doi.org/10.1016/j.ejca.2012.04.001.CrossRefPubMedGoogle Scholar
- 9.National Comprehensive Cancer Network [NCCN]. NCCN clinical practice guidelines in oncology (NCCN guidelines®). Vulvar cancer (squamous cell carcinoma). Version 2.2019—December 17, 2018. https://www.nccn.org/professionals/physician_gls/pdf/vulvar.pdf. Accessed 26 Jan 2019.
- 10.US Food and Drug Administration [FDA]. FDA approves rucaparib for maintenance treatment of recurrent ovarian, fallopian tube, or primary peritoneal cancer. https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm603997.htm. Accessed 26 Jan 2019.
- 14.US Food and Drug Administration [FDA]. Human papillomavirus vaccine. https://www.fda.gov/biologicsbloodvaccines/vaccines/approvedproducts/ucm172678.htm. Accessed 26 Jan 2019.
- 17.Newman PA, Logie CH, Lacombe-Duncan A, Baiden P, Tepjan S, Rubincam C, Doukas N, Asey F. Parents’ uptake of human papillomavirus vaccines for their children: a systematic review and meta-analysis of observational studies. BMJ Open. 2018;8(4):e019206. https://doi.org/10.1136/bmjopen-2017-019206.CrossRefPubMedPubMedCentralGoogle Scholar
- 26.European Organisation for Research and Treatment of Cancer [EORTC] Quality of Life Group. Questionnaires. https://qol.eortc.org/questionnaires/. Accessed 26 Jan 2019.